Trial · NCT06137183
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Clinical Remission at Week 12 | Arm A: Vixarelimab 720 mg Q2W | 11.1 | 95% Confidence Interval 3.85 to 28.06 | percentage of participants | |
| Percentage of Participants With Clinical Remission at Week 12 | Arm B: Vixarelimab 720 mg Q4W | 3.8 | 95% Confidence Interval 0.68 to 18.89 | percentage of participants | |
| Percentage of Participants With Clinical Remission at Week 12 | Arm C: Placebo | 11.5 | 95% Confidence Interval 4.00 to 28.98 | percentage of participants | |
| Percentage of Participants With Clinical Response at Week 12 | Arm A: Vixarelimab 720 mg Q2W | 29.6 | 95% Confidence Interval 15.85 to 48.48 | percentage of participants | |
| Percentage of Participants With Clinical Response at Week 12 | Arm B: Vixarelimab 720 mg Q4W | 19.2 | 95% Confidence Interval 8.51 to 37.88 | percentage of participants | |
| Percentage of Participants With Clinical Response at Week 12 | Arm C: Placebo | 26.9 | 95% Confidence Interval 13.70 to 46.08 | percentage of participants | |
| Percentage of Participants With Endoscopic Improvement at Week 12 | Arm A: Vixarelimab 720 mg Q2W | 11.1 | 95% Confidence Interval 3.85 to 28.06 | percentage of participants | |
| Percentage of Participants With Endoscopic Improvement at Week 12 | Arm B: Vixarelimab 720 mg Q4W | 3.8 | 95% Confidence Interval 0.68 to 18.89 | percentage of participants | |
| Percentage of Participants With Endoscopic Improvement at Week 12 | Arm C: Placebo | 19.2 | 95% Confidence Interval 8.51 to 37.88 | percentage of participants | |
| Percentage of Participants With Endoscopic Remission at Week 12 | Arm A: Vixarelimab 720 mg Q2W | 0 | 95% Confidence Interval 0.00 to 12.46 | percentage of participants | |
| Percentage of Participants With Endoscopic Remission at Week 12 | Arm B: Vixarelimab 720 mg Q4W | 0 | 95% Confidence Interval 0.00 to 12.87 | percentage of participants | |
| Percentage of Participants With Endoscopic Remission at Week 12 | Arm C: Placebo | 7.7 | 95% Confidence Interval 2.14 to 24.14 | percentage of participants | |
| Number of Participants With Adverse Events (AEs) | Arm A: Vixarelimab 720 mg Q2W | 13 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Arm B: Vixarelimab 720 mg Q4W | 14 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Arm C: Placebo | 9 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Arm A: Vixarelimab 720 mg Q2W to Vixarelimab 720 mg Q2W | 9 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Arm B: Vixarelimab 720 mg Q4W to Vixarelimab 720 mg Q4W | 5 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Arm C: Placebo to Vixarelimab 720 mg Q2W | 8 | Participants | ||
| Serum Concentration of Vixarelimab at Specified Timepoints | Arm A: Vixarelimab 720 mg Q2W | Week 0 | NA | Geometric Coefficient of Variation NA | micrograms per milliliter (µg/mL) |
| Serum Concentration of Vixarelimab at Specified Timepoints | Arm B: Vixarelimab 720 mg Q4W | Week 0 | NA | Geometric Coefficient of Variation NA | micrograms per milliliter (µg/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06137183/results